Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of B1344 in Patients With NAFLD
NCT07128797Phase 1Recruiting
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of b1344 in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (5 arms), sponsored by Tasly Biopharmaceuticals Co., Ltd. Primary endpoint: Frequency and severity of Adverse Events (AEs) and Serious Adverse Events at 113 days. Started Jul 2025; status: recruiting.
02
Drugs
b1344
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT07128797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128797.